Brief Report: Androgen Receptor Expression Is Associated With Male Predominance in Thymic Neuroendocrine Neoplasms [0.03%]
Christopher S Nabel,Chad B Sussman,Charles A Whittaker et al.
Christopher S Nabel et al.
Introduction: Neuroendocrine neoplasms represent a rare and poorly understood collection of malignancies. A better understanding of their biology is needed to improve treatment options. Male predominance to the incidence ...
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition [0.03%]
MET介导的携带KRAS G12C突变的非小细胞肺癌对Sotorasib耐药及联合靶向KRAS和MET治疗产生反应
Richard Riedel,Lea Ruge,Malte Verheyen et al.
Richard Riedel et al.
Introduction: KRAS G12C mutations define a molecularly distinct subset of NSCLC for which targeted therapy with sotorasib has exhibited clinical efficacy. However, acquired resistance is inevitable. MET amplification has ...
Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report [0.03%]
阿克替尼耐药的两个病例及端粒酶抑制剂联合治疗效果评估
David John McMahon,Alexius John,Foteini Kalofonou et al.
David John McMahon et al.
A number of drugs are in development for the treatment of ERBB2(HER2)-mutated NSCLC, including antibody-drug conjugates such as trastuzumab-deruxtecan and tyrosine kinase inhibitors such as zongertinib and sevabertinib. Herein, we report a ...
Histologic Grade 3 in Stage 1A Lung Adenocarcinoma: Survival Risks Comparable to Stage 1B [0.03%]
1A期肺腺癌组织学分级3的生存风险相当于1B期
Gyerim Park,Youngkyu Moon,Meejeong Kim et al.
Gyerim Park et al.
Introduction: Early stage NSCLC presents a significant risk of recurrence despite surgical resection. The International Association for the Study of Lung Cancer-proposed histologic grading system identifies high-grade tum...
Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study [0.03%]
小细胞肺癌免疫微环境生物标志物的探索：J-TAIL-2观察性研究
Masayuki Shirasawa,Makoto Nishio,Kadoaki Ohashi et al.
Masayuki Shirasawa et al.
Introduction: Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. This exploratory analysis from J-TAIL-2 aimed to identify markers of...
Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report [0.03%]
关于带有EML4-NTRK3融合的分泌性癌样肺癌腺癌术后辅助larotrectinib治疗：病例报告
Vladmir Cláudio Cordeiro de Lima,Breno Jeha Araújo,Felipe D&#x; Almeida Costa et al.
Vladmir Cláudio Cordeiro de Lima et al.
Secretory carcinoma of the lung is an exceptionally rare salivary gland-type malignancy, typically associated with NTRK fusions. We report a 71-year-old woman with pulmonary stage IIIA adenocarcinoma having salivary gland differentiation an...
Immune Doublet Checkpoint Inhibition in EGFR-Mutated NSCLC: A Fire That Fails to Illuminate the Orchard [0.03%]
免疫双重阻断在EGFR突变型NSCLC中并未照亮果园反而引燃了一场无效的火灾——对肿瘤免疫治疗耐药机制的研究思考
Richard Pham,Surein Arulananda
Richard Pham
Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study [0.03%]
ELEVATE研究中的早期NSCLC的治疗模式：亚洲患者的特征
Myung-Ju Ahn,Daniel Sw Tan,Morgan Windsor et al.
Myung-Ju Ahn et al.
Introduction: The management of early stage NSCLC is evolving with new therapies. Given the lack of guidelines for Asia Pacific, understanding the different factors affecting treatment decisions is key to effective clinic...
ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report [0.03%]
携带新型ZFPM2::ALK和TRIM24::ALK融合阳性肺癌的ALK抑制剂疗效：病例报告
Charles Hsu,Mohamed Yakoub,Michael Offin et al.
Charles Hsu et al.
Background: ALK fusion-positive NSCLC is driven by a range of fusion partners, most often EML4::ALK. The clinical impact, oncogenicity, and resistance mechanisms of rare, noncanonical ALK fusions remain underexplored. We ...
Detection of a Rare Intra-ALK Inversion and ALK Rearrangement in a Lung Adenocarcinoma Patient by FoundationOne Liquid CDx and Successful Treatment with Alectinib: Case Report [0.03%]
通过FoundationOne液体试剂盒检测到罕见的间变性淋巴瘤激酶（ALK）基因内倒位和重排并成功使用阿来替尼进行治疗的肺腺癌病例报告
Chiaki Kanno,Satoshi Takahashi,Masaru Hagiwara et al.
Chiaki Kanno et al.
A 50-year-old woman with stage IVB lung adenocarcinoma tested negative for driver mutations using the Oncomine Dx Target Test Multi-CDx system (Thermo Fisher Scientific, Waltham, MA). After undergoing chemotherapy and immunotherapy, Foundat...